APA
Nielsen L. K., Stege C., Lissenberg-Witte B., van der Holt B., Mellqvist U., Salomo M., Bos G., Levin M., Visser-Wisselaar H., Hansson M., van der Velden A., Deenik W., Coenen J., Hinge M., Klein S., Tanis B., Szatkowski D., Brouwer R., Westerman M., Leys R., Sinnige H., Haukås E., van der Hem K., Durian M., Gimsing P., van de Donk N., Sonneveld P., Waage A., Abildgaard N. & Zweegman S. (20210427). Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. : Haematologica.
Chicago
Nielsen Lene Kongsgaard, Stege Claudia, Lissenberg-Witte Birgit, van der Holt Bronno, Mellqvist Ulf-Henrik, Salomo Morten, Bos Gerard, Levin Mark-David, Visser-Wisselaar Heleen, Hansson Markus, van der Velden Annette, Deenik Wendy, Coenen Juleon, Hinge Maja, Klein Saskia, Tanis Bea, Szatkowski Damian, Brouwer Rolf, Westerman Matthijs, Leys Rineke, Sinnige Harm, Haukås Einar, van der Hem Klaas, Durian Marc, Gimsing Peter, van de Donk Niels, Sonneveld Pieter, Waage Anders, Abildgaard Niels and Zweegman Sonja. 20210427. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. : Haematologica.
Harvard
Nielsen L. K., Stege C., Lissenberg-Witte B., van der Holt B., Mellqvist U., Salomo M., Bos G., Levin M., Visser-Wisselaar H., Hansson M., van der Velden A., Deenik W., Coenen J., Hinge M., Klein S., Tanis B., Szatkowski D., Brouwer R., Westerman M., Leys R., Sinnige H., Haukås E., van der Hem K., Durian M., Gimsing P., van de Donk N., Sonneveld P., Waage A., Abildgaard N. and Zweegman S. (20210427). Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. : Haematologica.
MLA
Nielsen Lene Kongsgaard, Stege Claudia, Lissenberg-Witte Birgit, van der Holt Bronno, Mellqvist Ulf-Henrik, Salomo Morten, Bos Gerard, Levin Mark-David, Visser-Wisselaar Heleen, Hansson Markus, van der Velden Annette, Deenik Wendy, Coenen Juleon, Hinge Maja, Klein Saskia, Tanis Bea, Szatkowski Damian, Brouwer Rolf, Westerman Matthijs, Leys Rineke, Sinnige Harm, Haukås Einar, van der Hem Klaas, Durian Marc, Gimsing Peter, van de Donk Niels, Sonneveld Pieter, Waage Anders, Abildgaard Niels and Zweegman Sonja. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. : Haematologica. 20210427.